Features

Levitronix CEO Kurt Dasse on the company's roots at Thermo Fisher Scientific, why its magnetic levitation technology is so well-suited to implantable cardiac assist devices and how the medical device excise tax could force consolidation in the medical device industry.

Byron Hewett, the CEO of Cambridge, Mass.-based BioBehavioral Diagnostics, on the importance of being able to quantify the symptoms of Attention Deficit Hyperactivity Disorder, helping families cope with an ADHD member and how the Food & Drug Administration let the horse out of the barn when it comes to regulating the diagnostics industry.